SELLAS Life Sciences Q3 net loss widens on higher R&D costs

Overview

• US biopharma firm's Q3 net loss widened year-over-year on higher R&D and admin expenses

• Company ended Q3 with $134.7 mln in cash and cash equivalents

• Higher expenses reflect increased manufacturing, clinical trial and regulatory costs for pipeline programs

Outlook

• SELLAS expects topline primary endpoint results from Phase 3 REGAL trial of GPS this month

• Preliminary topline data from Phase 2 SLS009 trial in newly diagnosed AML expected in Q4 2026

• Company continuing preparations for clinical development of SLS009 in pancreatic cancer

Result Drivers

• R&D SPENDING - Higher research and development expenses due to increased manufacturing, clinical and regulatory consulting, and clinical trial costs for GPS program

• ADMIN COSTS - General and administrative expenses rose due to higher non-cash stock-based compensation and professional fees

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Sellas Life Sciences Group Inc is $32.50, about 286% above its November 11 closing price of $8.42

Reuters Recommended Reads

• Nov 12 - Sagimet Biosciences Q3 net loss widens on higher R&D costs

• Nov 10 - Cellectar Biosciences Q3 net loss widens on higher R&D costs

• Nov 10 - Liquidia Q3 loss widens on litigation charge, negating Yutrepia demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)